Very tight vs. tight control: what should be the criteria for pharmacologic therapy dose adjustment in diabetes in pregnancy? Evidence from randomized controlled trials by Caissutti, Claudia et al.
AOGS SYSTEMATIC REVIEW
Very tight vs. tight control: what should be the criteria for
pharmacologic therapy dose adjustment in diabetes in
pregnancy? Evidence from randomized controlled trials
CLAUDIA CAISSUTTI1 , GABRIELE SACCONE2 , ANDREA CIARDULLI3 &
VINCENZO BERGHELLA4
1Department of Experimental Clinical and Medical Science (DISM), Clinic of Obstetrics and Gynecology, University of
Udine, Udine, 2Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of
Naples Federico II, Naples, 3Department of Obstetrics and Gynecology, Catholic University of Sacred Heart, Rome, Italy,
and 4Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College of
Thomas Jefferson University, Philadelphia, PA, USA
Key words
Diabetes, pregnancy, diabetes mellitus,
gestational diabetes mellitus, insulin,
metformin
Correspondence
Vincenzo Berghella, Department of Obstetrics
and Gynecology, Division of Maternal-Fetal
Medicine, Thomas Jefferson University, 833
Chestnut, Philadelphia, PA 19107, USA.
E-mail: vincenzo.berghella@jefferson.edu
Conflict of interest
The authors have stated explicitly that there
are no conflicts of interest in connection with
this article.
Please cite this article as: Caissutti C, Saccone
G, Ciardulli A, Berghella V. Very tight vs.
tight control: what should be the criteria for
pharmacologic therapy dose adjustment in
diabetes in pregnancy? Evidence from
randomized controlled trials. Acta Obstet
Gynecol Scand 2018; 97:235–247.
Received: 31 July 2017
Accepted: 6 November 2017
DOI: 10.1111/aogs.13257
Abstract
Introduction. There is inconclusive evidence from randomized controlled trials
(RCTs) to support any specific criteria for pharmacologic therapy dose
adjustment in diabetes in pregnancy. Our objective was to analyze the criteria
for dose adjustment of pharmacologic treatment for diabetes mellitus (DM) in
pregnancy. Material and methods. Data sources: MEDLINE, OVID and
Cochrane Library were searched from their inception to September 2017.
Selection criteria included all trials of DM in pregnancy managed by oral
hypoglycemic agents or insulin reporting criteria for pharmacologic therapy
dose adjustment. RCTs in women with pregestational DM and gestational DM
(GDM) were included. For each trial, data regarding glucose values used for
pharmacologic therapy dose adjustment were extracted and carefully reviewed.
Results. Of 51 RCTs on therapy for GDM or pregestational DM, 17 (4230
women) were included as they reported criteria for pharmacologic therapy
dose adjustment. Most of them (88%, 15/17) included women with GDM
only. For RCTs including women with GDM, 12/16 (75%) used the two-step
approach, three (19%) the one-step approach and one (6%) either the one- or
two-step approach. Regarding the type of initial therapy, 13 (77%) RCTs used
different types and doses of insulin; nine (53%) used metformin; five (30%)
used glyburide; and one (6%) used placebo. In most RCTs, glucose monitoring
was assessed four times daily, i.e. fasting (all RCTs) and two hours (15 RCTs,
88%) after each of the three main meals – breakfast, lunch, and dinner. For
fasting glucose target, all used a value <105 mg/dL; nine (53%) used 95 mg/dL
as target. Of the 15 RCTs using a two-hour postprandial value as target, 11
(73%) had 120 mg/dL as cutoff. Regarding the criteria for pharmacologic
therapy dose adjustment, we found six different criteria. The majority of RCTs
(9/17, 53%) used either one or two values per week higher than the target
values, of which two-thirds used only one value (35% of total), and one-third
(18% of total) two values. Five RCTs (29%) used >50%, one (6%) >30%, and
one (6%) >20% of the values higher than the target value; one (6%) used the
appearance of glycosuria. Conclusions. When evaluating RCTs which included
criteria for pharmacologic GDM therapy dose adjustment, the most common
criterion for diagnosis was the two-step test, and the most common used
therapies were insulin and metformin. Regarding glucose monitoring, the most
common frequency was four times per day, fasting and two hours after each
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main meal, using as target glucose values 95 and 120 mg/dL, respectively.
Importantly, we found six different criteria for pharmacologic GDM therapy
dose adjustment, with the majority using very tight criteria of either one or
two values per week higher than the target values, of which two-thirds used
only one value, and one-third used two values.
Abbreviations: DM, diabetes mellitus; GMD, gestational diabetes mellitus; NPH,
neutral protamine Hagedorn; RCT, randomized controlled trial.
Introduction
Carbohydrate disorders in pregnancy, including gesta-
tional diabetes mellitus (GMD) and pregestational dia-
betes mellitus (DM), are the most common morbidities
complicating pregnancy, with short- and long-term con-
sequences to mothers, fetuses, and newborns. It has been
estimated that up to 6–7% or more of all pregnancies are
complicated by DM in pregnancy (1–52). The latest
reports from the International Diabetes Federation esti-
mate that, worldwide, approximately one in seven births
in 2015 were complicated by some form of hyperglycemia
during pregnancy (53).
Management for women with carbohydrate disorders
in pregnancy includes diet, physical activity, oral hypo-
glycemic agents or insulin as needed. The management of
those women aims to achieve the best possible glycemic
control, with normal or near normal glucose values while
avoiding hypoglycemia. This management is effective in
reducing maternal and neonatal morbidity and mortality
(3,9,24,31,38).
Nevertheless, the optimal schedule, frequency and tim-
ing of glucose monitoring remains disputable, as are the
glycemic metabolic goals. Moreover, there is no evidence
from randomized controlled trials (RCTs) to support
any specific criteria for pharmacologic therapy dose
adjustment.
Thus, the aim of this review was to analyze the criteria
for dose adjustment of pharmacologic treatment for DM
in pregnancy through a systematic review of RCTs.
Material and methods
Search strategy
This review was performed according to a protocol rec-
ommended for systematic review (54). The review proto-
col was designed a priori to define methods for
collecting, extracting, and analyzing data. The research
was conducted with the use of MEDLINE, OVID, and
Cochrane Library as electronic databases. The trials were
identified with the use of a combination of the following
text words: “gestational diabetes”, “GDM”, “diabetes in
pregnancy”, “therapy”, “treatment”, “insulin”, “oral
hypoglycemic”, “metformin”, “trial” and “randomized”
from the inception of each database to September 2017.
Review of articles also included the abstracts of all refer-
ences that were retrieved from the search. No restrictions
on language or geographic location were applied. In
addition, the reference lists of all identified articles were
examined to identify studies not captured by electronic
searches. The electronic search and the eligibility of the
studies were independently assessed by two authors
(C.C., G.S.). Differences were discussed with a third
reviewer (V.B.).
Study selection
Selection criteria included all RCTs of diabetes in preg-
nancy managed by oral hypoglycemic agents or insulin.
Trials in women with pregestational DM and trials in
women with GDM were included. Trials in women trea-
ted only with exercise or diet at the time of randomiza-
tion were excluded. Trials in women with impaired
glucose tolerance and trials not reporting criteria for dose
adjustment of pharmacologic treatment were also
excluded. We analyzed retrospective and prospective
studies.
Data extraction and risk of bias assessment
The risk of bias in each included study was assessed using
the criteria outlined in the Cochrane Handbook for Sys-
tematic Reviews of Interventions. Seven domains related to
risk of bias were assessed in each included trial since
Key message
The majority of trials used very tight criteria of either
one or two values per week higher than the target
values for pharmacologic diabetes therapy dose
adjustment.
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there is evidence that these issues are associated with
biased estimates of treatment effect: (i) random sequence
generation; (ii) allocation concealment; (iii) blinding of
participants and personnel; (iv) blinding of outcome
assessment; (v) incomplete outcome data; (vi) selective
reporting; and (vii) other bias. Review authors’ judgments
were categorized as “low risk”, “high risk” or “unclear
risk” of bias (54).
Outcomes and data extraction
For each trial, data regarding glucose values used for
pharmacologic therapy dose modification were extracted
and carefully reviewed. We also planned to review the
type of screening, type of initial therapy (for example
insulin vs. oral hypoglycemic agent), frequency of glucose
monitoring, and target glucose values. The types of DM
screening were defined as one step, i.e. 75 g two-hour
glucose load, and two-step, i.e. 50 g one-hour glucose
load, followed if abnormal by a 100 g three-hour glucose
load test.
The primary outcome was the incidence of macroso-
mia, as defined by the original trials (13 RCTs defined
macrosomia as a birthweight >4000 g, the other four
RCTs used a birthweight >90th percentile).
The secondary outcomes were cesarean delivery, mater-
nal hypoglycemia and neonatal hypoglycemia. Primary
and secondary outcomes were assessed for each criteria
used by the original trials, for example one or two values
higher than the target values, a cutoff based on percent-
age of abnormal glucose values, ultrasound criteria, or
symptoms.
Primary and secondary outcomes were also assessed in
sensitivity analyses according to type of therapy, i.e. oral
hypoglycemic agent or insulin.
We also aimed to compare a policy of very tight (i.e.
more restrictive) vs. tight (i.e. less restrictive) control for
diabetes in pregnancy to assess the best criteria for phar-
macologic therapy dose adjustment, using indirect meta-
analysis.
We considered a policy of very tight control to use the
following criteria:
• one or two values higher than the target values (i.e.
intervention group)
We considered a policy of tight control to use the fol-
lowing criteria:
• >50% higher than the target values (i.e. comparison
group)
Other criteria (for example >20% or >30% higher,
ultrasound criteria, symptoms) were not included in the
indirect meta-analysis.
Statistical analyses
To show robustness of our review, we aimed to perform
a meta-analysis for the primary outcome (i.e. incidence of
macrosomia) (54,55). To complete such analyses, we per-
formed an adjusted indirect meta-analysis to compare a
policy of very tight control with a policy of tight control
for diabetes in pregnancy, as previously described (56).
The adjusted indirect comparison meta-analysis was per-
formed according to the most widely applied indirect
comparison method by Bucher et al. In this method, the
randomization of each trial is maintained, and the direct
comparison is used to yield an indirect comparison
(55,56). In the indirect comparison, meta-analysis, data
were combined in a two-stage approach in which out-
comes were analyzed in their original study and then
summary statistics combined using standard summary
data meta-analysis techniques to give an overall measure
of effect (55,56).
The data analysis of the indirect meta-analysis was
completed independently by two authors (C.C., G.S.)
using REVIEW MANAGER v. 5.3 (The Nordic Cochrane
Center, Cochrane Collaboration, 2014, Copenhagen, Den-
mark). The completed analyses were then compared, and
any difference was resolved by discussion with a third
reviewer (V.B.) (54).
Data from each eligible study were extracted without
modification of original data onto custom-made data col-
lection forms. A 2 9 2 table was assessed for relative risk
(54).
Indirect meta-analysis was performed using the random
effects model of DerSimonian & Laird (54) to produce
summary treatment effects in terms of relative risk with
95% confidence interval (CI).
The meta-analysis was reported following the Preferred
Reporting Item for Systematic Reviews and Meta-analyses
(PRISMA) statement (57). Before data extraction, the
review was registered with the PROSPERO International
Prospective Register of Systematic Reviews
(CRD42016053067).
Results
We identified 51 RCTs on therapy for GDM or pregesta-
tional diabetes, and assessed these for eligibility (Figure 1)
(1–51). Of them, 34 were excluded, and therefore 17
including 4230 women were included (1–3,5–14,16–19).
Figure 2 shows the risk of bias of the included trials.
Most of them had low risk of bias in selection, attrition,
and reporting.
No trials compared differing criteria for pharmacologic
therapy dose adjustment. Most of them (88%, 15/17)
included women with GDM only (1–3,5,7–13,16–19).
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Refuerzo et al. (14) included women with type II preges-
tational diabetes only. Hickman et al. (6) included
women with both GDM and type II pregestational dia-
betes. For RCTs including women with GDM, 12/16
(75%) used the two-step test (2,5–13,18,19) and three tri-
als the one-step test (1,3,16). Spaulonci et al. (17) used
either the one- or two-step approach (17). Sample size
ranged from 21(14) to 1000 women (3). Regarding the
type of initial therapy, 13 (77%) trials used different types
and doses of insulin (NPH, regular short-acting, lispro)
(1,3,6–10,12–14,17–19), nine (53%) trials tested met-
formin (1,5,6,10–12,14,16,17), five (30%) trials tested gly-
buride (2,5,8,11,18), and one (6%) trial used placebo (2)
(Table 1).
Table 2 shows the management of women included in
trials. In most of them (14 RCTs, 82%) glucose
monitoring was assessed four times daily, i.e. fasting and
either one or two hours after each of the three main
meals – breakfast, lunch, and dinner (1–3,5,6,8,10–
14,16,18,19); two (12%) trials assessed four to seven times
daily, i.e. fasting, preprandial before lunch and dinner,
one and two hours after each main meal – breakfast,
lunch, and dinner (7,17). Only one (6%) trial carried out
monitoring nine times a day, i.e. fasting and one and two
hours after each main meal – breakfast, lunch, and dinner
(9). All 17 RCTs used fasting glucose as a target, and
100% had a value <105 mg/dL; nine (53%) used 95 mg/
dL as target. Of the 15 RCTs using the two-hour post-
prandial value as target, 11 (73%) had 120 mg/dL as cut-
off. Of the four RCTs using a one-hour postprandial
value as target, two (50%) had 120 mg/dL as cutoff, and
the others used 150 mg/dL (Table 2). One RCT also con-
sidered the Hb1Ac value (18).
Regarding the glucose values used for dose modifica-
tion:
• Nine trials (53%) used one or two values higher
than the target values (3,5,7,10–12,16,18,19) (i.e. very
tight control group); 6/17 (35%) used one value
higher than target values (3,5,7,10,18,19), and 3/17
(18%) used two values higher than target values
(11,12,16). Of these nine trials, five (56%) used their
criteria over 1 week (5,10,12,16,19), two over
2 weeks (3,11), one over either one or 2 weeks (7),
and one over 3 days (18).
• Five trials (29%) used >50% of the values higher than
the target values (2,6,8,9,14) (i.e. tight control group).
• One trial (6%) used >30% of the values higher than
the target values (17).
• One trial (6%) used >20% of the values higher than
the target values (1).
• One trial (6%) used appearance of glycosuria (13).
Table 3 shows individual data for the primary and sec-
ondary outcomes in the overall analysis. Indirect meta-
analysis showed no statistically significant difference in
the incidence of macrosomia comparing a very tight with
a tight policy (8.3 vs. 7.0%; relative risk 1.20, 95% CI
0.87–1.64). Tables 4 and 5 show primary and secondary
outcomes in sensitivity analyses in insulin- and met-
formin-only trials.
Discussion
This systematic review from 17 RCTs, including 4230
women, evaluated the criteria for pharmacologic therapy
dose adjustment in diabetes in pregnancy. We failed to
find any RCT comparing differing criteria for pharmaco-
logic therapy dose adjustment. The majority of the 17
RCTs included women with GDM (88%); used the two-
255 records
104 records after duplicates
151 records
100 records
excluded based
on title and/or
abstract
34 full-text articles
51 full-text articles
51 studies
included in
qualitative
synthesis
17 studies
included in
quantitative
synthesis
(meta-analysis)
assessed for
eligibility
excluded:
- No data on dose
- Medical therapy
started after
randomization
adjustment
available (n=32)
(n=2)
screened
removed
Identified through
database
searching
Figure 1. Flow diagram of studies identified in the systematic review.
PRISMA template (Preferred Reporting Item for Systematic Reviews
and Meta-analyses).
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step test (with 100 g glucose load as second step) for
GDM diagnosis (75%); insulin (77%) and metformin
(53%) as therapies; monitored glucose values four times
per day, i.e. fasting and usually two hours after each main
meal – breakfast, lunch and dinner (82%); and used as
targets a fasting glucose target of 95 mg/dL (53%) and
two hours of 120 mg/dL (65%). As described in a review
of the Endocrine Society from 2013, a fasting glucose tar-
get of <90 mg/dL is associated with a lower risk of
macrosomia and other outcomes in women with gesta-
tional diabetes, whereas this is unclear in pregestational
diabetes (58). Moreover, therapy adjustment based on the
results of postprandial, rather than preprandial, blood
glucose values in women with GDM improves glycemic
control and decreases the risk of neonatal hypoglycemia,
macrosomia, and cesarean delivery (59).
Regarding our main aim, i.e. evaluating criteria for
pharmacologic DM therapy dose adjustment, we found
six different criteria. The majority of RCTs (53%) used
either one or two values per week higher than the
target values, of which two-thirds used only one
value (35% of total), and one-third (18% of total) two
values.
There are at least 11 variables regarding management
of GDM which could affect the outcomes, macrosomia
etc. These include:
Figure 2. Assessment of risk of bias. (A) Summary of risk of bias for each trial; Plus sign: low risk of bias; minus sign: high risk of bias; question
mark: unclear risk of bias. (B) Risk of bias graph about each risk of bias item presented as percentages across all included studies. [Color figure
can be viewed at wileyonlinelibrary.com].
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• indications for screening (who)
• timing of screening (when)
• type of screening (one- vs. two-step) (how) (60,61)
• criteria for diagnosis
• criteria to start therapy using diet alone
• type of initial therapy (for example insulin vs. oral
hypoglycemic agent)
• dose and frequency of initial therapy
• frequency of glucose monitoring
• target glucose values
• criteria for pharmacologic therapy dose adjustment
• criteria for adding or switching pharmacologic therapy
While very tight (one or two abnormal target vales) vs.
tight criteria for pharmacologic therapy dose adjustment
did not seem to affect outcomes (Table 3), it is impossi-
ble to really assess this comparison given the other 10
variables listed above, which could not be controlled for.
Strengths of the study include the use of the most rig-
orous methodology for an indirect meta-analysis of RCTs.
We are not aware of any other meta-analysis evaluating a
policy of very tight vs. tight glycemic control to assess the
criteria for pharmacologic therapy dose adjustment in
diabetes in pregnancy. The variables which may affect
pregnancy outcomes in GDM management were carefully
reviewed. The most common management strategies for
GDM used in RCTs were identified.
There are several limitations in our study. Four RCTs
used a different definition of macrosomia. No trials com-
paring a policy of very tight vs. tight glycemic control to
assess the criteria for pharmacologic therapy dose adjust-
ment in diabetes in pregnancy could be identified. There-
fore, a standard meta-analysis was not feasible. An
indirect meta-analysis has wide statistically inconsistency
compared with standard meta-analysis. In addition, the
risk of overestimation could be high when the indirect
comparison of interest relies on only a few trials. The
clinical heterogeneity within the trials was very high. Tri-
als included used different protocol management, differ-
ent diagnostic tests, different sample size, different initial
therapy, different glucose monitoring, different target glu-
cose values. Moreover, not all RCTs considered the same
outcomes.
Finally, the majority of included RCTs considered neu-
tral protamine Hagedorn (NPH) and regular insulin to
be the only options. Nowadays, the use of insulin ana-
logues, in particular the rapid-acting bolus analogues
aspart and lispro, achieve postprandial targets with less
hypoglycemia compared with regular insulin, with similar
fetal outcomes, and.the long-acting insulin analogues
glargine and detemir appear safe with similar maternal/fe-
tal outcomes compared with NPH (62). We included
only trials of diabetes in pregnancy managed by oralTa
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hypoglycemic agents or insulin. Trials in women treated
only with exercise or diet at the time of randomization
were excluded. Exercise in pregnancy has been shown to
reduce the risk of diabetes in both normal-weight and
overweight and obese women (63–66), as well as to
improve pregnancy outcome in those with GDM (67).
When evaluating RCTs which included criteria for
pharmacologic GDM therapy dose adjustment, the most
common criteria for GDM diagnosis was the two-step
test, and the most common therapies used were insulin
and metformin. Regarding glucose monitoring, the most
common frequency was four times per day, i.e. fasting
and after each main meal, using a fasting level of 95 mg/
dL and a two-hour level of 120 mg/dL as targets. Impor-
tantly, we found six different criteria for pharmacologic
GDM therapy dose adjustment, with the majority using
very tight criteria of either one or two values per week
higher than the target values, of which two-thirds used
only one value (35% of total), and one-third (18% of
total) two values. While very tight (one or two abnormal
target vales) vs. tight criteria for pharmacologic therapy
dose adjustment did not seem to affect outcomes
(Table 3), it is impossible to really assess this comparison
given no head-to-head RCTs with this study design.
Future well-designed, properly powered RCTs are needed
to answer this important clinical question.
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